Best LL-37 5mg and 10mg Peptides GMP Factory

LL-37

LL-37

Other names:CAP-18, Cathelicidin, antibacterial peptide LL-37, hCAP18

LL-37, the only human member of the cathelicidin family of antimicrobial peptides. It is a naturally occurring peptide, a short chain of amino acids, that is part of the human immune system’s defense against infections. As an cathelicidins peptide, LL-37 has antimicrobial activity. In addition, a large number of experiments have shown that it also has the function of immune regulation.

Production capacity: Provide customization

Large Factory Professional Manufacturers & Factory

Production Carried OUT Under CGMP Regulation and Trackable

ISO9001 & ISO14000

SHARE THIS

pinterest-logo 50x50 twitter logo Tumblr-LOGO 50x50 LinkedIn_logo_50x50LinkedIn_logo_50x50 LinkedIn_logo_50x50

Get a Bulk quotation

If you need a larger quantity. Please fill in the form, our BD (Business Development) will provide you with a competitive quotation.

LL-37 Peptide dosage calculator

Referenced Citations

[1]Shi Y, Li C, Wang M, et al.  Cathelicidin-DM is an  Antimicrobial Peptide from Duttaphrynus melanostictus and Has Wound-Healing Therapeutic Potential. ACS Omega. 2020;5(16):9301-9310. Published 2020 Apr 14. doi:10.1021/acsomega.0c00189  [pubmed]

[2]Kościuczuk EM, Lisowski P, Jarczak J, et al. Cathelicidins: family of antimicrobial peptides. A review. Mol Biol Rep. 2012;39(12):10957-10970. doi:10.1007/s11033-012-1997-x [pubmed]

[3]Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. 2013;191(10):4895-4901. doi:10.4049/jimmunol.1302005 [pubmed]

[4]Pahar B, Madonna S, Das A, Albanesi C, Girolomoni G. Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections. Vaccines (Basel). 2020;8(3):517. Published 2020 Sep 10. doi:10.3390/vaccines8030517 [pubmed]

[5]Gordon YJ, Huang LC, Romanowski EG, Yates KA, Proske RJ, McDermott AM. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular

surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res. 2005;30(5):385-394. doi:10.1080/02713680590934111 [pubmed]

[6]Ridyard KE, Overhage J. The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent. Antibiotics (Basel). 2021;10(6):650. Published 2021 May 29. doi:10.3390/antibiotics10060650 [pubmed]

[7]Nagaoka I, Tamura H, Reich J. Therapeutic Potential of Cathelicidin Peptide LL-37, an Antimicrobial Agent, in a Murine Sepsis Model. Int J Mol Sci. 2020;21(17):5973. Published 2020 Aug 19. doi:10.3390/ijms21175973 [pubmed]

[8]Alalwani SM, Sierigk J, Herr C, et al. The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils. Eur J Immunol. 2010;40(4):1118-1126. doi:10.1002/eji.200939275 [pubmed]

[9]Kuroda K, Okumura K, Isogai H, Isogai E. The Human Cathelicidin Antimicrobial Peptide LL-37 and Mimics are Potential Anticancer Drugs. Front Oncol. 2015;5:144. Published 2015 Jun 30. doi:10.3389/fonc.2015.00144 [pubmed]

[10]Amer, L. S., Bishop, B. M., and van Hoek, M. L. (2010). Antimicrobial and antibiofilm activity of cathelicidins and short, synthetic peptides against Francisella. Biochem. Biophys. Res. Commun. 396, 246–251. doi:10.1016/j.bbrc.2010.04.073 [pubmed]

[11]Bowdish, D. M., Davidson, D. J., Speert, D. P., and Hancock, R. E. (2004). The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J. Immunol. 172, 3758–3765. [pubmed]

[12] Braff, M. H., Zaiou, M., Fierer, J., Nizet, V., and Gallo, R. L. (2005). Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens. Infect. Immun. 73, 6771–6781. doi:10.1128/IAI.73.10.6771-6781.2005 [Journal]

[13] Brandenburg, L.-O., Merres, J., Albrecht, L.-J., Varoga, D., and Pufe, T. (2012). Antimicrobial peptides: multifunctional drugs for different applications. Polymers 4, 539–560. doi:10.3390/polym4010539 [pubmed]

[14]Dean, S. N., Bishop, B. M., and van Hoek, M. L. (2011b). Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus. BMC Microbiol. 11:114. doi:10.1186/1471-2180-11-114 [pubmed]

[15]Elssner, A., Duncan, M., Gavrilin, M., and Wewers, M. D. (2004). A novel P2×7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J. Immunol. 172, 4987–4994.[pubmed]

Author of this article:

Dr. Jean Zeng graduated from king’s college london Faculty of Life Sciences & Medicine.

Scientific Journal paper Author:

Gabriel Garcia de Carvalho

Department of Physiology and Pathology, São Paulo State University (Unesp), School of Dentistry at Araraquara,  Araraquara, São Paulo, Brazil

MJ Lappin

Correspondence to: Department of Restorative Dentistry, Centre for Dentistry, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, UK.

François Niyonsaba

Correspondence: François Niyonsaba, Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.

Lhousseine Touqui

Corresponding author. “Sorbonne Université”, INSERM UMR_S 938, “Centre de Recherche Saint-Antoine” (CRSA), Paris, France.

Sabina Noreen Wuersching

Department of Conservative Dentistry and Periodontology, University Hospital, LMU Munich, Goethestrasse 70, 80336, Munich, Germany

In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. Polypeptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.

Author of this article:

Dr. Jean Zeng graduated from king's college london Faculty of Life Sciences & Medicine.

Scientific Journal paper Author:

Stephen C. Bain
Diabetes Research Group, Swansea University Medical School, Swansea, SA2 8PP, UK
Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, SA2 8QA, UK

In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. Polypeptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.